Nicotine Replacement Therapy

Phase 2

Nicotine Replacement Therapy is one of 5 therapeutic programs targeting Tobacco Use Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Tobacco Use DisorderNot yet recruiting

Dual Use of Cigarettes and E-CigarettesNot yet recruiting

Tobacco Use DisorderPreclinical

Not yet recruiting

Dual Use of Cigarettes and E-CigarettesPhase 2

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Tobacco Use Disorder

#DrugCompanyPhaseTrials

Chantix

PPrism Pharmaceuticals

Phase 2

2 2

Chantix

Pfizer

Phase 1

1 3

Nicotine Replacement Therapy

VVA Office of Research and Development

Phase 2

1 4

Wellbutrin

GGlaxo Dba Glaxosmithkline

Preclinical

1 5

Nicotine Replacement Therapies

NNYU Langone Health

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

PreclinicalNot yet recruiting

Tobacco Use Disorder

NCT07714200

Q3 2031

Phase 2Not yet recruiting

Dual Use of Cigarettes and E-Cigarettes

NCT07754578

Clinical

Trials by Indication[1]

Dual Use of Cigarettes and E-cigarettes1 trial

High-Dose Nicotine Replacement Therapy for Quitting Cigarettes and E-cigarettes

Not yet recruiting·MMedical University of South Carolina·Phase 2·NCT07754578·321 enrolled

Tobacco Use Disorder1 trial

Abstinence Reinforcement Therapy for Veterans Who Smoke Tobacco and Are Experiencing Homelessness

Not yet recruiting·VVA Office of Research and Development·Preclinical·NCT07714200·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Nicotine Replacement Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Nicotine Replacement Therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — VA Office of Research and Development company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: VVA Office of Research and Development

Nicotine Replacement Therapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2030

Q3 2031

Trials by Indication[1]

Dual Use of Cigarettes and E-cigarettes1 trial

Tobacco Use Disorder1 trial

References

Drug Info

Quick Facts

Related News